COVID-19 antibody drug trial halted early — little data to show
NCT ID NCT05081388
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a new antibody drug (REGN14256) alone or with imdevimab in 25 adults with mild COVID-19 and no risk factors for severe illness. The goal was to check safety and whether the drug could lower virus levels. However, the trial was terminated early, so we have no clear results on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REGN14256 and imdevimab (antibody drugs)
- What this could lead to
- If successful, this could provide a treatment option for COVID-19 patients without severe disease risk.
- What could go wrong
- The trial was terminated early with only 25 participants, so no conclusions can be drawn. Early-phase studies often fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AGA Clinical Trials
Hialeah, Florida, 33012, United States
-
Advanced Diagnostics Clinic, River Oaks Hospital and Clinics
Houston, Texas, 77027, United States
-
Ark Clinical Research
Long Beach, California, 90806, United States
-
Bio-Medical Research LLC
Miami, Florida, 33184, United States
-
Carolina Medical Research
Clinton, South Carolina, 29325, United States
-
Charisma Research and Medical Center
Miami Lakes, Florida, 33014, United States
-
Chicago Clinical Research Institute
Chicago, Illinois, 60607, United States
-
Forte Family Practice
Las Vegas, Nevada, 89103, United States
-
Global Medical Trials
Miami, Florida, 33174, United States
-
IACT Health
Columbus, Georgia, 31904, United States
-
NYC H+H / Jacobi Medical Center
The Bronx, New York, 10461, United States
-
New York Health and Hospitals / Lincoln
The Bronx, New York, 10451, United States
-
Olive Branch Family Medical Center
Olive Branch, Mississippi, 38654, United States
-
PNS Clinical Research, LLC
Mission Viejo, California, 92691, United States
-
PharmaTex Research, LLC
Amarillo, Texas, 79109, United States
-
Project 4 Research, Inc.
Miami, Florida, 33125, United States
-
Regeneron Research Site
La Mesa, California, 91941, United States
-
Regeneron Research Site
Ft. Pierce, Florida, 34982, United States
-
Regeneron Research Site
Loxahatchee Groves, Florida, 33470, United States
-
Regeneron Research Site
Winter Park, Florida, 32789, United States
-
Regeneron Research Site
Ames, Iowa, 50010, United States
-
Regeneron Research Site
Marrero, Louisiana, 70072, United States
-
Regeneron Research Site
Wilmington, North Carolina, 28401, United States
-
Regeneron Research Site
Dayton, Ohio, 45409, United States
-
Regeneron Research Site
Houston, Texas, 77030, United States
-
Regeneron Research Site
Houston, Texas, 77093, United States
-
Triple O Research Institute, P.A.
West Palm Beach, Florida, 33407, United States
-
Universal Medical and Research Center, LLC
Miami, Florida, 33126, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill keep High-Risk COVID-19 patients out of the hospital?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Millions of vaccine records scoured for rare side effects
- Scientists probe why lung disease raises COVID-19 risk
- New rapid test could spot COVID and flu in minutes
- New saliva test could diagnose COVID-19 in under an hour